Key result
Troglitazone cuts aortic fatty streak lesions by ~6 percentage points in hyperlipidemic mice.
Answers are grounded in this paper and cite their sources.
Atherosclerotic coronary heart disease is a common complication of the insulin resistance syndrome that can occur with or without diabetes mellitus. Thiazolidinediones (TZDs), which are insulin-sensitizing antidiabetic agents, can modulate the development of atherosclerosis not only by changing the systemic metabolic conditions associated with insulin resistance but also by exerting direct effects on vascular wall cells that express peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a nuclear receptor for TZDs. Here we show that troglitazone, a TZD, significantly inhibited fatty streak lesion formation in apolipoprotein E-knockout mice fed a high-fat diet (en face aortic surface lesion areas were 6.9+/-2.5% vs 12.7+/-4.7%, P<0.05; cross-sectional lesion areas were 191 974+/-102 911 micrometer(2) vs 351 738+/-175 597 micrometer(2), P<0.05; n=10). Troglitazone attenuated hyperinsulinemic hyperglycemia and increased high density lipoprotein cholesterol levels. In the aorta, troglitazone markedly increased the mRNA levels of CD36, a scavenger receptor for oxidized low density lipoprotein, presumably by upregulating its expression, at least in part, in the macrophage foam cells. These results indicate that troglitazone potently inhibits fatty streak lesion formation by modulating both metabolic extracellular environments and arterial wall cell functions.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2001) studied Atherosclerosis (n=10). Troglitazone vs. Control (high-fat diet without troglitazone) was evaluated on En face aortic surface fatty streak lesion area (p=<0.05). Troglitazone inhibited en face aortic fatty streak lesion area in apoE-knockout mice fed a high-fat diet.
Synapse has enriched 10 related papers. Consider them for comparative context: